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abstract
The role of clinical researchers is vital to cancer progress. The teaching, research, and leadership roles that
academic oncologists hold need to be accounted for and appropriately compensated. National metrics are
currently inexistent, but are necessary to move the oncology research field forward. Clinical research and routine
clinical care must be harmoniously integrated without competing. This article reviews the national landscape of
clinical cancer research and proposes a call for action.
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CANCER CLINICAL RESEARCH CHALLENGES
In the last 30 years, cancer biology discoveries have
led to improved patient care. These advances stem
from clinical research mainly performed at academic
centers. Clinical trial portfolios require substantial
research and administrative time.1 This effort is
directly related to patient care, but not clinically
benchmarked. Academic medical oncologists face
the challenge of adapting to compensation models,2
usually measured in relative value units (RVUs) and
developed wholly on benchmarks based on patient-
facing clinical work,3 which limits time and effort for
non–RVU-generating academic activities. Clinical
research effort has no standardized measure to
support salaries of physicians conducting clinical
research.
In June 2019, ASCO invited oncology division chiefs
and department chairs to meet to exchange ideas and
management strategies. Among the issues identified
was a high degree of heterogeneity in how institu-
tions handled clinician workload. There was significant
variation in expected number of clinic sessions and
inpatient service time, RVU benchmarks, and support
for non–RVU-generating clinical work. The current
trend of academic centers competing with private
hospitals further encroaches on the research mission.
Lack of benchmarks for the academic mission was
uniformly perceived as affecting physician work/life
balance and burnout4-6 and highlighted the need for
national standards.
PHENOTYPES OF CLINICIANS IN ONCOLOGY
Fourteen participating leaders reviewed the current
state within their institutions. These leaders repre-
sented medical oncology divisions and departments
across the United States, from community-based
practices to university-based matrix or free-standing
National Cancer Institute (NCI) –designated cancer
centers.7 Three main phenotypes of medical oncology
faculty were apparent:
1. Clinicians: physicians both in private practice
models and academic oncologists, whose pri-
mary focus is patient care. These are typically full-
time clinicians with little educational or research
responsibilities, whomay enroll patients in clinical
trials.
2. Clinical researchers: academic physicians, who
have significant patient care and clinical trial
responsibility (design, oversight, accrual, analy-
sis, presentation, and publication). Clinical
researchers may also conduct other kinds of
research (epidemiology, health service). Although
research is usually funded by grants or contracts,
the funding rarely supports the investigator salary.
3. Physician scientists: academic physicians, who
have peer-reviewed funding and spend the ma-
jority of their time on non–patient-facing research
(eg, laboratory-based, population sciences, or
other health services research). They see patients
to a smaller extent and may or may not be in-















funding supports a percentage of their salary, often
with an institutional cost-share mechanism.
Table 1 summarizes the clinical roles played by these
physicians and highlights heterogeneity. At community-
based centers, clinicians are typically full-time physicians
(6-9 clinic sessions per week; median, 8 sessions) with
salaries linked to clinical productivity (Table 2). These
physicians generally see a mixture of tumor types and
benign hematology. Academic efforts are possible by ap-
proval, with hours deducted from outpatient expectations,
sometimes leading to reduced salary. At all academic
centers, the three phenotypes were recapitulated. The
clinician phenotype resembles community practice. Phy-
sician scientist research efforts are funded by grants or
other research mechanisms, with cost-share above the
National Institutes of Health salary cap generally covered by
the cancer center; these physicians have fewer clinical
duties (approximately 25% of full-time clinical equivalent
[cFTE], with a median of 1 clinic per week; range, 1-2
sessions). In contrast, for clinical researchers, the greatest
variability in clinical sessions was observed.
CLINICAL RESEARCHER DILEMMA
This article addresses the lack of appropriate metrics and
support for the clinical research phenotype. For clinical
researchers, the median time dedicated to clinical duties is
approximately 50% (range, 40%-80%) of the cFTE. No-
tably, the percentage of the cFTE of clinical researchers
TABLE 1. Summary of the Clinical Workload by Physician Category
Setting Clinical Oncologist Clinical Researcher Physician Scientist
Community
Outpatient sessionsa 8-9 NA NA
Inpatient weeksb 0-6 NA NA
Academic
Outpatient sessions (median)a 6-9 (8) 4-6 (4) 0.5-2 (2)
Inpatient weeks (average)b 0-6 2-12 (5) 0-4
Abbreviation: NA, not applicable.
aOne outpatient session, 4 hours per week.
bInpatient, weeks per year.
TABLE 2. RVUs and Salary Benchmarks From 2016 to 2018



















Abbreviations: AAMC, American Association of Medical Colleges; CPSC, Clinical Practice Solutions Center; MGMA, Medical Group
Management Association; RVU, relative value unit.
aRanges for assistant professor to full professor.
does not overlap with that of clinicians or physician sci-
entists, creating this de facto category of clinically ori-
ented physicians dedicated to clinical research, producing
valuable efforts typically not protected through grants or
other mechanisms. The lack of national benchmarks to
reflect clinical research, teaching, or administrative effort is
a consistent challenge, because institutions use diverse
sets of expectations for various activities.
There are two main RVU benchmarking categories, based
on self-reported data from hospitals and practices,
for clinical productivity and salary. Academic practice
benchmarks are assessed by the American Association of
Medical Colleges and its associated Clinical Practice So-
lutions Center (AAMC/CPSC)8 or by the University Health
System Consortium (UHC). Private oncology practice
benchmarks are provided by the Medical Group Man-
agement Association (MGMA), the American Medical
Group Association, SullivanCotter, or ECG Management
Consultants9 (Table 2). Most academic practices use the
AAMC/CPSC or UHC benchmarks, and community prac-
tices often use the MGMA or SullivanCotter benchmarks,
but no standardization was seen among our 14 centers.
Curiously, the AAMC/CPSC benchmarks calculate higher
RVUs and lower salaries than the MGMA benchmarks
(Table 2). This is a potential impediment to implementation
of effective models for academic oncology.2,10,11
Medical oncology generates 30% to 50% of net hospital
margins, although this is hard to quantify accurately.12 This
real bottom line does not derive from RVUs generated
through evaluation and management coding, which con-
tributes on average 25% of medical oncologists’ salaries13;
the profit is through revenues from cancer therapies.14,15
Infrequently, when the profit goes to the cancer center,
substantial funds might be available to compensate faculty
clinical research efforts. More commonly, internal accounting
and complicated fund flows set by administrators and senior
leadership direct faculty salaries. Division chiefs or de-
partment chairs are responsible for budgets that include not
only salaries but sometimes clinic management as well, over
which they usually have little control. The one constant in
funds flow is a transfer of dollars, using the net margins
created by oncology services, to support RVU-based salaries.
However, there is no consistent model of institutional support
to cover clinical research time, which is a critical driver of
improvements in cancer clinical care and a major attraction
for patients seeking care at academic centers.
NEED FOR CLINICAL RESEARCH NATIONAL BENCHMARKS
Clinical researchers spend considerable time studying,
writing, and teaching as subject matter experts within their
particular tumor types and have many required activities,
besides clinic visits, that are not easily accounted for in
RVU-based compensation models. Clinical research duties
are varied and increase with trial complexity and volume.
Clinical research is heavily regulated through the In-
ternational Conference on Harmonisation Good Clinical
Practice (GCP), which aligns to the Code of Federal Reg-
ulations.16 Evolving regulations and increasing regulatory
burdens are imposed on investigators without compensa-
tory resources.17,18 ASCO measured trial acuity to describe
the complexity of trials,19,20 and the National Compre-
hensive Cancer Network published benchmarks in 2007,21
but these analyses may be outdated. In our survey, the
dedicated effort needed to successfully perform all required
GCP tasks22 was 40% to 60% of the cFTE. Clinical trial
contracts with the commercial sector or awards from NCI
mechanisms do not provide adequate support for clinical
investigator time and effort. Furthermore, the reconciliation
of clinical trial budgets is often a retrospective measure of
effort already spent that does not directly compensate
an investigator’s time. Alternative sources of support for
clinical research and clinical researchers are therefore
required. If an academic medical oncology clinical re-
searcher workforce is to be maintained to improve the
outcomes of patients with cancer through research, it is
critical that these efforts are appropriately recognized,
measured, and compensated at all institutions. Successful
support for this critical workforce requires a degree of
stability and a common language of effort allocation, even
as academic centers attempt to become cost competitive in
an increasingly consolidated marketplace.
CALL FOR ACTION
Division chiefs and department chairs of medical oncology,
connected through ASCO myConnection, started a di-
alogue on the need for clinical research benchmarks. The
consensus was that an appropriate benchmark for clinical
researchers is a partitioning between clinical care and
clinical research, with at least 50% protected time for
clinical research; institutional or other official support is
required; and objective measures for clinical research
activities are needed, given the clinical nature and uni-
formly recognized value of the effort in the absence of RVU
attribution.
The complex business of academic medicine needs to
integrate the vital role of clinical researchers and adopt
metrics necessary to move the oncology research field
forward without being tied to generation of RVUs. The
teaching, research, and leadership roles that academic
oncologists hold need to be accounted for and compen-
sated.6 We are calling for action to develop clinical research
benchmarks. ASCO is ideally positioned to help create
standards aligned with funding recommendations to sup-
port clinical researchers.
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